Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.

Charlestown, Massachusetts Thursday, January 9, 2025, 14:30 Hrs [IST] ...

A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, ...

Leveraging Acadia’s extensive expertise in developing and commercializing advanced therapies for neurological disorders ... comprises two marketed drugs — Nuplazid (pimavanserin) and the ...

A groundbreaking discovery in drug development, spearheaded by Indian-origin American scientist Dr. Indrajeet Sharma, ...

This comprehensive analysis examines Biohaven's current position, future prospects, and potential risks in the competitive landscape of neurological drug development. Biohaven's strategic focus ...

The main groups involved in the medication discrepancies were gastrointestinal (n = 55; 20.2% of discrepancies), neurologic (n = 55; 20.2%), and cardiologic (n = 34; 12.5%). In the ...

the effects of newer antiseizure medications on their children was unknown," said Adam Hartman, M.D., program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS).